Superworth

Cytokinetics EPS CYTK

Diluted earnings per share by quarter and over the last twelve months, from 2010.

Last 12 months, to Jun 30, 2026
−$7.21
Latest quarter, Q2 FY26
−$1.50
Fiscal year 2025
−$6.52

Cytokinetics' earnings per share was −$7.21 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$1.50.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$6.52n/a
FY2024−$5.27n/a
FY2023−$5.45n/a
FY2022−$4.25n/a
FY2021−$2.83n/a
FY2020−$2.01n/a
FY2019−$2.12n/a
FY2018−$1.95n/a
FY2017−$2.57−879%
FY2016$0.33n/a
FY2015−$0.97n/a
FY2014−$0.43n/a
FY2013−$1.32n/a
FY2012−$2.47n/a
FY2011−$4.32n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$1.50n/a−$7.21
Q1 FY26−$1.67n/a−$6.83
Q4 FY25−$1.49n/a−$6.52
Q3 FY25−$2.55n/a−$6.30
Q2 FY25−$1.12n/a−$5.11
Q1 FY25−$1.36n/a−$5.30
Q4 FY24−$1.27n/a−$5.27
Q3 FY24−$1.36n/a−$5.38
Q2 FY24−$1.31n/a−$5.37
Q1 FY24−$1.33n/a−$5.40
Q4 FY23−$1.38n/a−$5.45
Q3 FY23−$1.35n/a−$5.52

Against its peers

Companies in Drug Manufacturers - General nearest Cytokinetics' size, closest first, today.

CompanyEPS, 12 monthsGrowth
CYTKCytokinetics−$7.21
TGTXTG Therapeutics$2.74+641% a year
PTGXProtagonist Therapeutics$1.03+47% a year
CORTCorcept Therapeutics$0.42−63% a year
ALKSAlkermes plc.$0.38−82% a year
BMRNBiomarin Pharmaceutical$0.37−89% a year
AMRXAmneal Pharmaceuticals$0.49+4800% a year
LGNDLigand Pharmaceuticals$9.40
KNSAKiniksa Pharmaceuticals International$0.97+2325% a year
JAZZJazz Pharmaceuticals$14.62
INDVIndivior Pharmaceuticals$2.78+227% a year
Peer median$1.00

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Cytokinetics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.